Citi raised the firm’s price target on Bristol Myers (BMY) to $66 from $64 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q1 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol-Myers Squibb Signals Confident Path After Q1 Call
- Bristol Myers reports Q1 adjusted EPS $1.58, consensus $1.42
- Bristol Myers backs FY26 adjusted EPS view $6.05-$6.35, consensus $6.26
- Bristol Myers Squibb Posts Q1 2026 Results, Reaffirms Outlook
- Options Volatility and Implied Earnings Moves Today, April 30, 2026